A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence

Raymond F. Anton, Helen Pettinati, Allen Zweben, Henry R. Kranzler, Bankole Johnson, Michael J. Bohn, Mary E. McCaul, Robert Anthenelli, Ihsan M Salloum, Gantt Galloway, James Garbutt, Robert Swift, David Gastfriend, Antero Kallio, Sakari Karhuvaara

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The opiate antagonist nalmefene has been shown in 2 single-site studies to reduce alcohol consumption and relapse drinking in alcohol-dependent individuals. This safety and preliminary multisite efficacy study evaluated 3 doses of nalmefene (5, 20, or 40 mg) in a double-blind comparison to placebo over a 12-week treatment period in 270 recently abstinent outpatient alcohol-dependent individuals. Participants concomitantly received 4 sessions of a motivational enhancement therapy (with a medication compliance component) delivered from trained counselors. Although more subjects in the active medication groups terminated the study early secondary to adverse events, the rates did not differ significantly from that of placebo. The 20-mg/d group experienced more insomnia, dizziness, and confusion, while the 5-mg group also had more dizziness and the 40-mg group had more nausea than the placebo group. Most of these symptoms were mild and improved over time. Although all subjects had a reduction in heavy drinking days, craving, γ-glutamyl transferase, and carbohydrate-deficient transferrin concentrations over the course of the study, there was no difference between the active medication and placebo groups on these measures. The time to first heavy drinking day was also not significantly different between the placebo and the active treatment groups. This relatively small multisite trial showed that nalmefene was reasonably well tolerated in recently abstinent alcoholics. However, possibly because of variation among the sites or the comparatively small sample size, there was no evidence of superior efficacy outcomes with nalmefene treatment.

Original languageEnglish
Pages (from-to)421-428
Number of pages8
JournalJournal of Clinical Psychopharmacology
Volume24
Issue number4
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Fingerprint

Alcoholism
Placebos
Dizziness
Alcohol Drinking
Drinking
Opiate Alkaloids
Therapeutics
Confusion
Medication Adherence
Sleep Initiation and Maintenance Disorders
Alcoholics
Transferases
Sample Size
Nausea
Outpatients
Alcohols
nalmefene
Safety
Recurrence

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Anton, R. F., Pettinati, H., Zweben, A., Kranzler, H. R., Johnson, B., Bohn, M. J., ... Karhuvaara, S. (2004). A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. Journal of Clinical Psychopharmacology, 24(4), 421-428. https://doi.org/10.1097/01.jcp.0000130555.63254.73

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. / Anton, Raymond F.; Pettinati, Helen; Zweben, Allen; Kranzler, Henry R.; Johnson, Bankole; Bohn, Michael J.; McCaul, Mary E.; Anthenelli, Robert; Salloum, Ihsan M; Galloway, Gantt; Garbutt, James; Swift, Robert; Gastfriend, David; Kallio, Antero; Karhuvaara, Sakari.

In: Journal of Clinical Psychopharmacology, Vol. 24, No. 4, 01.08.2004, p. 421-428.

Research output: Contribution to journalArticle

Anton, RF, Pettinati, H, Zweben, A, Kranzler, HR, Johnson, B, Bohn, MJ, McCaul, ME, Anthenelli, R, Salloum, IM, Galloway, G, Garbutt, J, Swift, R, Gastfriend, D, Kallio, A & Karhuvaara, S 2004, 'A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence', Journal of Clinical Psychopharmacology, vol. 24, no. 4, pp. 421-428. https://doi.org/10.1097/01.jcp.0000130555.63254.73
Anton, Raymond F. ; Pettinati, Helen ; Zweben, Allen ; Kranzler, Henry R. ; Johnson, Bankole ; Bohn, Michael J. ; McCaul, Mary E. ; Anthenelli, Robert ; Salloum, Ihsan M ; Galloway, Gantt ; Garbutt, James ; Swift, Robert ; Gastfriend, David ; Kallio, Antero ; Karhuvaara, Sakari. / A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. In: Journal of Clinical Psychopharmacology. 2004 ; Vol. 24, No. 4. pp. 421-428.
@article{a19e016cdc764b8b8ef0a857d44657a1,
title = "A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence",
abstract = "The opiate antagonist nalmefene has been shown in 2 single-site studies to reduce alcohol consumption and relapse drinking in alcohol-dependent individuals. This safety and preliminary multisite efficacy study evaluated 3 doses of nalmefene (5, 20, or 40 mg) in a double-blind comparison to placebo over a 12-week treatment period in 270 recently abstinent outpatient alcohol-dependent individuals. Participants concomitantly received 4 sessions of a motivational enhancement therapy (with a medication compliance component) delivered from trained counselors. Although more subjects in the active medication groups terminated the study early secondary to adverse events, the rates did not differ significantly from that of placebo. The 20-mg/d group experienced more insomnia, dizziness, and confusion, while the 5-mg group also had more dizziness and the 40-mg group had more nausea than the placebo group. Most of these symptoms were mild and improved over time. Although all subjects had a reduction in heavy drinking days, craving, γ-glutamyl transferase, and carbohydrate-deficient transferrin concentrations over the course of the study, there was no difference between the active medication and placebo groups on these measures. The time to first heavy drinking day was also not significantly different between the placebo and the active treatment groups. This relatively small multisite trial showed that nalmefene was reasonably well tolerated in recently abstinent alcoholics. However, possibly because of variation among the sites or the comparatively small sample size, there was no evidence of superior efficacy outcomes with nalmefene treatment.",
author = "Anton, {Raymond F.} and Helen Pettinati and Allen Zweben and Kranzler, {Henry R.} and Bankole Johnson and Bohn, {Michael J.} and McCaul, {Mary E.} and Robert Anthenelli and Salloum, {Ihsan M} and Gantt Galloway and James Garbutt and Robert Swift and David Gastfriend and Antero Kallio and Sakari Karhuvaara",
year = "2004",
month = "8",
day = "1",
doi = "10.1097/01.jcp.0000130555.63254.73",
language = "English",
volume = "24",
pages = "421--428",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence

AU - Anton, Raymond F.

AU - Pettinati, Helen

AU - Zweben, Allen

AU - Kranzler, Henry R.

AU - Johnson, Bankole

AU - Bohn, Michael J.

AU - McCaul, Mary E.

AU - Anthenelli, Robert

AU - Salloum, Ihsan M

AU - Galloway, Gantt

AU - Garbutt, James

AU - Swift, Robert

AU - Gastfriend, David

AU - Kallio, Antero

AU - Karhuvaara, Sakari

PY - 2004/8/1

Y1 - 2004/8/1

N2 - The opiate antagonist nalmefene has been shown in 2 single-site studies to reduce alcohol consumption and relapse drinking in alcohol-dependent individuals. This safety and preliminary multisite efficacy study evaluated 3 doses of nalmefene (5, 20, or 40 mg) in a double-blind comparison to placebo over a 12-week treatment period in 270 recently abstinent outpatient alcohol-dependent individuals. Participants concomitantly received 4 sessions of a motivational enhancement therapy (with a medication compliance component) delivered from trained counselors. Although more subjects in the active medication groups terminated the study early secondary to adverse events, the rates did not differ significantly from that of placebo. The 20-mg/d group experienced more insomnia, dizziness, and confusion, while the 5-mg group also had more dizziness and the 40-mg group had more nausea than the placebo group. Most of these symptoms were mild and improved over time. Although all subjects had a reduction in heavy drinking days, craving, γ-glutamyl transferase, and carbohydrate-deficient transferrin concentrations over the course of the study, there was no difference between the active medication and placebo groups on these measures. The time to first heavy drinking day was also not significantly different between the placebo and the active treatment groups. This relatively small multisite trial showed that nalmefene was reasonably well tolerated in recently abstinent alcoholics. However, possibly because of variation among the sites or the comparatively small sample size, there was no evidence of superior efficacy outcomes with nalmefene treatment.

AB - The opiate antagonist nalmefene has been shown in 2 single-site studies to reduce alcohol consumption and relapse drinking in alcohol-dependent individuals. This safety and preliminary multisite efficacy study evaluated 3 doses of nalmefene (5, 20, or 40 mg) in a double-blind comparison to placebo over a 12-week treatment period in 270 recently abstinent outpatient alcohol-dependent individuals. Participants concomitantly received 4 sessions of a motivational enhancement therapy (with a medication compliance component) delivered from trained counselors. Although more subjects in the active medication groups terminated the study early secondary to adverse events, the rates did not differ significantly from that of placebo. The 20-mg/d group experienced more insomnia, dizziness, and confusion, while the 5-mg group also had more dizziness and the 40-mg group had more nausea than the placebo group. Most of these symptoms were mild and improved over time. Although all subjects had a reduction in heavy drinking days, craving, γ-glutamyl transferase, and carbohydrate-deficient transferrin concentrations over the course of the study, there was no difference between the active medication and placebo groups on these measures. The time to first heavy drinking day was also not significantly different between the placebo and the active treatment groups. This relatively small multisite trial showed that nalmefene was reasonably well tolerated in recently abstinent alcoholics. However, possibly because of variation among the sites or the comparatively small sample size, there was no evidence of superior efficacy outcomes with nalmefene treatment.

UR - http://www.scopus.com/inward/record.url?scp=3242660877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242660877&partnerID=8YFLogxK

U2 - 10.1097/01.jcp.0000130555.63254.73

DO - 10.1097/01.jcp.0000130555.63254.73

M3 - Article

C2 - 15232334

AN - SCOPUS:3242660877

VL - 24

SP - 421

EP - 428

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -